No Data
No Data
Rongchang Biotech (09995) plans to renew Ernst & Young Huaming as an A-share auditor and internal control auditor for 2024
Rongchang Biotech (09995) announced that the company plans to renew Ernst & Young Huaming Certified Public Accountants (Special General Partnership) (...
Rongchang Biotech (09995) plans to apply for comprehensive credit lines totaling no more than 5.5 billion yuan from banks and other financial institutions
Rongchang Biotech (09995) issued an announcement. According to the company's operating needs and financial situation, the company plans to go to the bank in 2024...
Rongchang Biotech (09995) will not distribute cash dividends and bonus shares in 2023
Rongchang Biotech (09995) announced that the company's 2023 profit distribution plan is: no cash dividends,...
Rongchang Biotech (09995) plans to use no more than 300 million yuan of its own funds to purchase wealth management products
Rongchang Biotech (09995) announced that the company held the 11th meeting of the 2nd board of directors and the 8th meeting of the 2nd board of supervisors on March 27, 2024 to review and pass the “Proposal on Using Own Funds for Cash Management”, agreeing that the company will use no more than RMB 300 million of its own capital to purchase financial products with high security, good liquidity, and that purchasing institutions are not limited to banks, securities companies and other financial institutions for cash management.
REMEGEN: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Rongchang Biotech (688331.SH) reported 2023 annual results, with a net loss of 1,511 billion yuan, an increase in year-on-year losses
Rongchang Biotech (688331.SH) released its 2023 annual report. The company achieved operating income of 10 during the reporting period...
No Data